A Phase 2, Single Arm Study of CG0070 Combined With Pembrolizumab in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Mar 2025 According to a CG Oncolgy media release, company data from this study will be presented at the 40th Annual European Association of Urology (EAU) Congress taking place in Pink Area N101, Ifema, Madrid, Spain on March 24, 2025.
25 Sep 2024 Status changed from active, no longer recruiting to completed.
01 Aug 2024 Primary endpoint (Complete response rate in patients) has been met, according to results published in the Nature Medicine.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com